China Nuokang Bio-Pharma Falls on NY Debut
By wchung | 23 Apr, 2026
Shares of China Nuokang Bio-Pharmaceutical Inc. fell nearly 4 percent in their trading debut Thursday after pricing at $9 per American depositary share, below their expected range.
The China-based biopharmaceutical company, which specializes in blood and cardiovascular treatments, had expected the initial public offering of 5 million ADSs to price between $10 and $12.
The company said net proceeds from the offering totaled about $32.9 million. The company plans to use the funds to grow its sales and marketing platform, for new acquisitions, for research and to expand manufacturing facilities.
Shares, which trade under the symbol “NKBP” on the Nasdaq, fell 33 cents, or 3.7 percent, to close at $8.67 with about 2.3 million shares changing hands during the session.
12/10/2009 4:53 PM NEW YORK (AP)
Recent Articles
- White House Accuses China of Industrial-Scale Distilling of AI Models
- AI Turns Engineers and Project Managers into 'Builders'
- US Farmers Bet on Peas and Lentils on GLP-1-Related Protein Maxxing Trend
- Lee's Visit Produces 73 S. Korea-Vietnam Business Deals
- Biggest IPO Wave Ever Creates $3 Trillion Value on Zero Profits
- Marijuana Products Reclassified As Less-Dangerous Drug
- China's Global EV Push Backed by Ambition and Hard Domestic Landscape
- Keurig Dr Pepper Beats As Strong Beverage Demand Offsets Coffee Weakness
- Huawei to Invest $2.6 Billion for Leadership in Smart Driving Tech
- Iran Shows Off Control over Strait with Action Video Footage